I don’t even come remotely close to being an expert on Pharma but IMHO Torrent Pharma is not cheap.
Let me quote Graham’s advise on EPS:
“Don’t take a single year’s earnings seriously. The second is: if you do pay attention to short-term earnings, look out for booby traps in the per-share earnings figures”.
TTM EPS for Torrent is 73.
Given the blockbuster sales of abilify and nexium and problem for competitors, we can annualise half year EPS for FY16 – which comes to upwards of 110.
That makes the stock look cheap on P/E metric.
But question we have to ask is is this earnings sustainable? Based on my limited understanding, it might not be. So if we aggressively assume 30% EPS growth rate for FY15 earnings, sustainable EPS might comes to 55 (FY16), 72 (FY17), 93 (FY18).
Assuming 20 P/E ratio for FY17 earnings, stock has fully priced that in.
So one can say only an enterprising investor who has intricate understanding of the Torrent business can invest at these levels.
Disc: Invested at current levels, 3% of portfolio, not looking to add more unless something changes significantly